Amarantus Bioscience Holdings, Inc. - FORM 10-K - EX-32.1 - EXHIBIT 32.1 - April 17, 2013

Attached files

file filename
10-K - FORM 10-K - Amarantus Bioscience Holdings, Inc.mainbody.htm
EX-10.34 - EXHIBIT 10.34 - Amarantus Bioscience Holdings, Inc.ex10_34.htm
EX-31.1 - EXHIBIT 31.1 - Amarantus Bioscience Holdings, Inc.ex31_1.htm
EX-31.2 - EXHIBIT 31.2 - Amarantus Bioscience Holdings, Inc.ex31_2.htm
EX-32.2 - EXHIBIT 32.2 - Amarantus Bioscience Holdings, Inc.ex32_2.htm
EX-10.33 - EXHIBIT 10.33 - Amarantus Bioscience Holdings, Inc.ex10_33.htm
EX-10.35 - EXHIBIT 10.35 - Amarantus Bioscience Holdings, Inc.ex10_35.htm
EX-10.32 - EXHIBIT 10.32 - Amarantus Bioscience Holdings, Inc.ex10_32.htm

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Amarantus BioScience Holdings, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gerald E. Commissiong, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date: April 16, 2013 By: /s/ Gerald E. Commissiong
 

Gerald E. Commissiong

Chief Executive Officer (Principal Executive Officer)

 

Amarantus Bioscience Holdings, Inc. Reports